Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-04-05
2011-04-05
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S002600, C514S04400A
Reexamination Certificate
active
07919098
ABSTRACT:
The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly, the present invention provides for methods for preventing, treating or delaying neoplasm in a mammal using an ErbB-3 protein, a nucleic acid encoding an ErbB-3 protein or a functional fragment thereof. The present invention also provides for isolated nucleic acids encoding an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, substantially purified extracellular domain of the ErbB-3 protein, or a functional fragment thereof and antibodies that bind to an epitope in an extracellular domain of the ErbB-3 protein, or a functional fragment thereof. The present invention further provides for pharmaceutical compositions and/or vaccines comprising the extracellular domain of the ErbB-3 protein, or a functional fragment thereof, or nucleic acids encoding and antibodies binding to such extracellular domain or functional fragments thereof.
REFERENCES:
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5686102 (1997-11-01), Gross et al.
patent: 5736154 (1998-04-01), Fuisz
patent: 5741511 (1998-04-01), Lee et al.
patent: 5820859 (1998-10-01), Kraus et al.
patent: 5886039 (1999-03-01), Kock et al.
patent: 5941868 (1999-08-01), Kaplan et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6197801 (2001-03-01), Lin
patent: 6258374 (2001-07-01), Friess et al.
patent: 7285649 (2007-10-01), Akita et al.
patent: 2004/0197332 (2004-10-01), Ullrich et al.
patent: 2005/0136494 (2005-06-01), Akita et al.
patent: 0 896 586 (1991-06-01), None
patent: 0 502 927 (1997-10-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO 91/08214 (1991-06-01), None
patent: WO 97/35885 (1997-10-01), None
patent: WO 98/02540 (1998-01-01), None
patent: WO 98/17797 (1998-04-01), None
patent: WO 98/30704 (1998-07-01), None
patent: WO 98/35036 (1998-08-01), None
patent: WO 01/87334 (2001-11-01), None
patent: WO 03/013602 (2003-02-01), None
patent: WO 2006/091209 (2006-08-01), None
patent: WO 2008/100624 (2008-08-01), None
Plowman et al (PNAS, 1990, 87:4905-4909).
Kraus et al (PNAS, 1989, 86:9193-9197).
Lee et al (Cancer Research, 2001, 61:4467-4473).
Lee et al (Cancer Research, 2001, 61:4467-4473).
Kraus et al (PNAS 1989, 9193-9197).
Alimandi et al., 1995, “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.” Oncogene 10:1813-1821.
Auerbach & Auerbach, 1994, “Angiogenesis inhibition: A review.” Pharmacol. Ther. 63(3):265-311.
Bei et al,, 1999, “Immune Responses to all ErbB family receptors detectable in serum of cancer patients.” Oncogene 18(6):1267-1275.
Chan et al., 1995, “Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.” J. Biol. Chem. 270:22608-22613.
Chen et al., 1996, “An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4” J Biol. Chem. 271:7620-7629.
Cooper, 2000,The Cell; A molecular approach, “Section 13: Cell Signaling; Receptor Protein-Tyrosine Kinase,” 2ndedition. ASM Press, Washington DC, pp. 1-6, Accessed Sep. 15, 2005 from http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cooper.
Curti, 1993, “Physical barriers to drug delivery in tumors” Crit. Rev. in Oncology/Hematology 14:29-39.
Dermer, 1994, “Another Anniversary for the War on Cancer.” Bio/technology 12:320.
Drebin et al., 1988, “Monoclonal antibodies reactive with distinct domains of theneuoncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.” Oncogene 2:273-277.
Fendly et al., 1990, “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2
euGene Product.” Cancer Res. 50:1550-1558.
Freshney, 1983, Culture of Animal cells: A manual of Basic Technique. Alan R. Liss., Inc. New York.
Gellner & Brenner, 1999, “Analysis of 148 kb of genomic DNA around the wntl locus of Fugu rubripes.” Genome Res 9(3):251-258.
Genbank Accesion No. AF056116, “Fugu rubripes serine/threonine kinase receptor type1, All-1 related protein (ALR), fugu hedgehog (fhh), Ikaros-like, wnt1, wnt10b, ARF3, erbB3, PAS1, and L41 ribosomal protein genes, complete cds; LRP1 gene, partial cds; and unknown genes,” dated Apr. 15, 1999.
Genbank Accesion No. M29366, “Human epidermal growth factor receptor (ERBB3) mRNA, complete cds,” dated Apr. 23, 1993.
Genbank Accession No. U29339, “Rattus norvegicus ErbB3/Her3 precursor mRNA, complete cds,” dated Dec. 5, 2001.
Gura, 1997, “Systems for identifying new drugs are often faulty.” Science 278:1041-1042.
Hamid, 2004, “Emerging Treatments in Oncology: Focus on Tyrosine Kinase (erbB) Receptor Inhibitors.” J Am. Pharm Assoc. 44:52-58.
Hellyer et al., 1995, “Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein.” Gene 165(2):279-284.
Holbro et al., 2003, “The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.” Proc. Natl. Acad. Sci. 100:8933-8938.
Hudson & Souriau, 2003, “Engineered antibodies.” Nat. Med. 9:129-134.
International Search Report of Application No. PCT/AU00/00671, dated Aug. 30, 2000.
International Search Report of Application No. PCT/CN03/00217, dated Jun. 5, 2003.
Jain, 1994, “Barriers to drug delivery in solid tumors.” Sci. Am. 271:58-65.
Kasprzyk et al., 1992, “Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies.” Cancer Res. 52:2771-2776.
Klapper et al., 1997, “A Subclass of Tumor-Inhibitory Monoclonal Antibodies to Erb-2/HER2 Blocks Crosstalk with Growth Factor Receptors.” Oncogene 14:2099-2109.
Klapper et al., 1999, “The ErB-2/HER2 Oncoprotein of Human Carcinomas May Function soley as a shared coreceptor for multiple Stroma-Derived Growth Factors.” Proc. Natl. Acad. Sci 96:4995-5000.
Kraus et al., 1989, “Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors.” Proc. Natl. Acad. Sci. 86:9193-9197.
Lab Vision NeoMarkers data sheet (Ab105) “c-erbB-3/HER-3 Ab-5 (Clone H3.105.5; same as Ab105)” Accessed Feb. 23, 2008 from http://www.labvision.com.
Lee et al., 2001, “A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.” Cancer Res 61:4467-4473.
Lillehoj et al., 1993, “Adjuvanticity of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and Corynebacterium parvum with respect to host immune response to coccidial antigens.” Avian Dis 37(3):731-740.
Mendrola et al., 2002, “The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes.” J. Biol. Chem. 27:4704-4712.
Park et al., 1999, “Induction of the Tat-Binding Protein 1 Gene Accompanies the Disabling of Oncogenic ErbB receptor tyrosine kinaes.” Proc. Natl. Acad. Sci 96:6434-6438.
Pinkas-Kramarski et al., 1998, “The Oncogenic ErbB-2/ErbB-3 Heterodimer is a Surrogate Receptor fo Epidermal Growth Factor and Betacellulin.” Oncogene 16:1249-1258.
Plowman et al., 1990, “Molecular cloning and expression of an additional epidermal growth factor receptor-related gene.” Proc. Natl. Acad. Sci 87:4905-4909.
Ram et al., 1996, “Mitogenic Activity of Neu Differentiation Factor//Heregulin Mimics that of Epidermal Growth Factor and Insulin-Like Growth Factor-I in Human Mammary epithelial cells.” J. cell. Physiol 169:589-596.
Ratiff et al, 1992, “Role of the im
Goddard Laura B
Jones Day
Zensun ( Shanghai ) Sci & Tech Co., Ltd.
LandOfFree
ErbB-3 based methods and compositions for treating neoplasms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ErbB-3 based methods and compositions for treating neoplasms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ErbB-3 based methods and compositions for treating neoplasms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711530